These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 31156618)

  • 1. The Challenges and Promise of Complement Therapeutics for Ocular Diseases.
    Park DH; Connor KM; Lambris JD
    Front Immunol; 2019; 10():1007. PubMed ID: 31156618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement System and Potential Therapeutics in Age-Related Macular Degeneration.
    Park YG; Park YS; Kim IB
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34202223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lutein and Factor D: two intriguing players in the field of age-related macular degeneration.
    Tian Y; Kijlstra A; Webers CAB; Berendschot TTJM
    Arch Biochem Biophys; 2015 Apr; 572():49-53. PubMed ID: 25637656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting complement components C3 and C5 for the retina: Key concepts and lingering questions.
    Kim BJ; Mastellos DC; Li Y; Dunaief JL; Lambris JD
    Prog Retin Eye Res; 2021 Jul; 83():100936. PubMed ID: 33321207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
    Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
    J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the alternative complement pathway.
    Fearon DT
    CRC Crit Rev Immunol; 1979 Nov; 1(1):1-32. PubMed ID: 162484
    [No Abstract]   [Full Text] [Related]  

  • 7. Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option.
    Qin S; Dong N; Yang M; Wang J; Feng X; Wang Y
    J Immunol Res; 2021; 2021():9945725. PubMed ID: 34368372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-Reactive Protein As a Mediator of Complement Activation and Inflammatory Signaling in Age-Related Macular Degeneration.
    Chirco KR; Potempa LA
    Front Immunol; 2018; 9():539. PubMed ID: 29599782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of Ocular Complement Activation by Inflammatory Stimuli and Intraocular Inhibition of Complement Factor D in Animal Models.
    Crowley MA; Delgado O; Will-Orrego A; Buchanan NM; Anderson K; Jaffee BD; Dryja TP; Liao SM
    Invest Ophthalmol Vis Sci; 2018 Feb; 59(2):940-951. PubMed ID: 29450541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the alternative complement pathway in vitreous is controlled by genetics in age-related macular degeneration.
    Loyet KM; Deforge LE; Katschke KJ; Diehl L; Graham RR; Pao L; Sturgeon L; Lewin-Koh SC; Hollyfield JG; van Lookeren Campagne M
    Invest Ophthalmol Vis Sci; 2012 Sep; 53(10):6628-37. PubMed ID: 22930722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic control of complement activation at the level of the central component C3.
    Ricklin D; Lambris JD
    Immunobiology; 2016 Jun; 221(6):740-6. PubMed ID: 26101137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement regulation in the eye: implications for age-related macular degeneration.
    Wilke GA; Apte RS
    J Clin Invest; 2024 May; 134(9):. PubMed ID: 38690727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-related macular degeneration: a complementopathy?
    Kijlstra A; Berendschot TT
    Ophthalmic Res; 2015; 54(2):64-73. PubMed ID: 26159686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of complement and Toll-like receptors as a novel approach to treat inflammatory diseases-C3 or C5 emerge together with CD14 as promising targets.
    Barratt-Due A; Pischke SE; Nilsson PH; Espevik T; Mollnes TE
    J Leukoc Biol; 2017 Jan; 101(1):193-204. PubMed ID: 27581539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The complement regulatory protein CD59: insights into attenuation of choroidal neovascularization.
    Schnabolk G; Tomlinson S; Rohrer B
    Adv Exp Med Biol; 2014; 801():435-40. PubMed ID: 24664728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The case for complement and inflammation in AMD: open questions.
    Karagianni N; Adamis AP
    Adv Exp Med Biol; 2010; 703():1-7. PubMed ID: 20711703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased membrane complement regulators in the retinal pigmented epithelium contributes to age-related macular degeneration.
    Ebrahimi KB; Fijalkowski N; Cano M; Handa JT
    J Pathol; 2013 Apr; 229(5):729-42. PubMed ID: 23097248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking properdin, the alternative pathway, and anaphylatoxin receptors ameliorates renal ischemia-reperfusion injury in decay-accelerating factor and CD59 double-knockout mice.
    Miwa T; Sato S; Gullipalli D; Nangaku M; Song WC
    J Immunol; 2013 Apr; 190(7):3552-9. PubMed ID: 23427256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration.
    Yaspan BL; Williams DF; Holz FG; Regillo CD; Li Z; Dressen A; van Lookeren Campagne M; Le KN; Graham RR; Beres T; Bhangale TR; Honigberg LA; Smith A; Henry EC; Ho C; Strauss EC;
    Sci Transl Med; 2017 Jun; 9(395):. PubMed ID: 28637922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.
    Williams AL; Gullipalli D; Ueda Y; Sato S; Zhou L; Miwa T; Tung KS; Song WC
    Kidney Int; 2017 Jun; 91(6):1386-1397. PubMed ID: 28139294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.